BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanchala DS, Bhatt LK, Prabhavalkar KS. Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells. Front Pharmacol 2017;8:270. [PMID: 28559846 DOI: 10.3389/fphar.2017.00270] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Diep YN, Kim TJ, Cho H, Lee LP. Nanomedicine for advanced cancer immunotherapy. Journal of Controlled Release 2022;351:1017-1037. [DOI: 10.1016/j.jconrel.2022.10.004] [Reference Citation Analysis]
2 Yun C, Hong J, Yoon A. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol 2022;13:953410. [DOI: 10.3389/fimmu.2022.953410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Makuku R, Seyedmirzaei H, Tantuoyir MM, Rodríguez-Román E, Albahash A, Mohamed K, Moyo E, Ahmed AO, Razi S, Rezaei N. Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article. Int Immunopharmacol 2022;105:108580. [PMID: 35121225 DOI: 10.1016/j.intimp.2022.108580] [Reference Citation Analysis]
4 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Shen CH, Chou CC, Lai TY, Hsu JE, Lin YS, Liu HY, Chen YK, Ho IL, Hsu PH, Chuang TH, Lee CY, Hsu LC. ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation. Front Cell Dev Biol 2021;9:642625. [PMID: 33996800 DOI: 10.3389/fcell.2021.642625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dailey KM, Allgood JE, Johnson PR, Ostlie MA, Schaner KC, Brooks BD, Brooks AE. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. Future Microbiol 2021;16:341-68. [PMID: 33754804 DOI: 10.2217/fmb-2020-0245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Wu Y, Li J, Shin HJ. Self-assembled Viral Nanoparticles as Targeted Anticancer Vehicles. Biotechnol Bioprocess Eng 2021;:1-14. [PMID: 33584104 DOI: 10.1007/s12257-020-0383-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: Challenges and solutions. Current Problems in Cancer 2021;45:100639. [DOI: 10.1016/j.currproblcancer.2020.100639] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
9 Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y, Liu J, Jaime-Ramirez AC, Hong B, Geng F, Guo D, Bystry D, Phelphs M, Quadri H, Lee TJ, Kaur B. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Neuro Oncol 2019;21:1131-40. [PMID: 31063549 DOI: 10.1093/neuonc/noz079] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
10 Menotti L, Avitabile E. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.Int J Mol Sci. 2020;21. [PMID: 33167582 DOI: 10.3390/ijms21218310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
11 Cervera-Carrascon V, Quixabeira DCA, Havunen R, Santos JM, Kutvonen E, Clubb JHA, Siurala M, Heiniö C, Zafar S, Koivula T, Lumen D, Vaha M, Garcia-Horsman A, Airaksinen AJ, Sorsa S, Anttila M, Hukkanen V, Kanerva A, Hemminki A. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Mol Ther Oncolytics 2020;17:47-60. [PMID: 32322662 DOI: 10.1016/j.omto.2020.03.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhang Y, Xin Q, Zhang JY, Wang YY, Cheng JT, Cai WQ, Han ZW, Zhou Y, Cui SZ, Peng XC, Wang XW, Ma Z, Xiang Y, Su XL, Xin HW. Transcriptional Regulation of Latency-Associated Transcripts (LATs) of Herpes Simplex Viruses. J Cancer 2020;11:3387-99. [PMID: 32231745 DOI: 10.7150/jca.40186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Marayati R, Quinn CH, Beierle EA. Immunotherapy in Pediatric Solid Tumors-A Systematic Review. Cancers (Basel) 2019;11:E2022. [PMID: 31847387 DOI: 10.3390/cancers11122022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
14 Luo Y, Lin C, Ren W, Ju F, Xu Z, Liu H, Yu Z, Chen J, Zhang J, Liu P, Huang C, Xia N. Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma. Mol Ther Oncolytics 2019;15:153-65. [PMID: 31720372 DOI: 10.1016/j.omto.2019.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
15 Gruntman AM, Flotte TR. The rapidly evolving state of gene therapy. FASEB J 2018;32:1733-40. [PMID: 31282760 DOI: 10.1096/fj.201700982R] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
16 Drayman N, Patel P, Vistain L, Tay S. HSV-1 single-cell analysis reveals the activation of anti-viral and developmental programs in distinct sub-populations. Elife 2019;8:e46339. [PMID: 31090537 DOI: 10.7554/eLife.46339] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 18.8] [Reference Citation Analysis]
17 DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev 2019;144:35-56. [PMID: 31279729 DOI: 10.1016/j.addr.2019.07.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
18 Drayman N, Patel P, Vistain L, Tay S. HSV-1 single cell analysis reveals anti-viral and developmental programs activation in distinct sub-populations.. [DOI: 10.1101/566489] [Reference Citation Analysis]
19 Ma W, He H, Wang H. Oncolytic herpes simplex virus and immunotherapy.BMC Immunol. 2018;19:40. [PMID: 30563466 DOI: 10.1186/s12865-018-0281-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
20 LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med 2018;7:35. [PMID: 30426287 DOI: 10.1186/s40169-018-0214-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 14.6] [Reference Citation Analysis]
21 Struzik J, Szulc-Dąbrowska L. NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives. Cancers (Basel) 2018;10:E426. [PMID: 30413032 DOI: 10.3390/cancers10110426] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
22 Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol 2018;13:671-80. [PMID: 30416535 DOI: 10.2217/fvl-2018-0068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. Designer Oncolytic Adenovirus: Coming of Age. Cancers (Basel) 2018;10:E201. [PMID: 29904022 DOI: 10.3390/cancers10060201] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 11.6] [Reference Citation Analysis]
24 Martin NT, Bell JC. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Mol Ther 2018;26:1414-22. [PMID: 29703699 DOI: 10.1016/j.ymthe.2018.04.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 15.8] [Reference Citation Analysis]
25 Tang Y, Guo J, Wang T, Zhao K, Liu J, Gao J, Tian Z, An T, Cai X. CRISPR/Cas9‐mediated 2‐sgRNA cleavage facilitates Pseudorabies virus editing. FASEB j 2018;32:4293-301. [DOI: 10.1096/fj.201701129r] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]